卵巢癌二次肿瘤细胞减灭术联合或不联合腹腔热灌注化疗后的并发症:一项随机II期试验的分析
该探索性分析纳入83例铂敏感复发性卵巢癌患者,评估二次肿瘤细胞减灭术联合或不联合腹腔热灌注化疗后30天内并发症。CTCAE≥3级并发症占40%,<3级占60%,无围手术期死亡。≥3级组术后化疗启动时间较<3级组略延迟(34天 vs 31天,P=.017),但中位无进展生存期(11.2 vs 14.9个月,P=.186)和中位总生存期(46.9 vs 68.2个月,P=.053)无显著差异。
要点
- 二次肿瘤细胞减灭术联合或不联合腹腔热灌注化疗后,CTCAE≥3级并发症发生率为40%(33/83)。
- ≥3级并发症组术后化疗启动时间34天,<3级组31天,差异有统计学意义(P=.017)。
- ≥3级与<3级并发症组的中位无进展生存期和中位总生存期均无显著差异。
核心结论
- 二次肿瘤细胞减灭术联合或不联合腹腔热灌注化疗后的术后并发症与化疗启动轻度延迟相关,但未显著影响肿瘤学结局。
研究设计与样本
- 对一项随机II期试验中入组的铂敏感复发性卵巢癌患者进行的探索性分析,共纳入83例符合条件患者。
- 术后30天内发生的并发症采用不良事件通用术语标准(CTCAE)5.0版分级,仅评估血红蛋白和血小板水平。
- 患者按CTCAE分级≥3级和<3级并发症分组。
主要发现
- 83例患者中,33例(40%)发生≥3级并发症,50例(60%)发生<3级并发症;贫血和腹腔感染最常见。
- 无围手术期死亡。
- ≥3级并发症组术后化疗启动时间为34天(范围18-60天),<3级组为31天(范围21-43天),P=.017。
- ≥3级与<3级并发症组的中位无进展生存期分别为11.2个月(95%CI:9.3-14.4)和14.9个月(95%CI:11.3-16.5),P=.186,无显著差异。
- ≥3级与<3级并发症组的中位总生存期分别为46.9个月(95%CI:34-NE)和68.2个月(95%CI:52.1-NE),P=.053,无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess postoperative complications after secondary cytoreductive surgery (SCS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC), we conducted an exploratory analysis of patients with platinum-sensitive recurrent ovarian cancer enrolled in a randomized phase II trial. METHODS: Complications occurring within 30 days of surgery were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0; only hemoglobin and platelet levels were assessed. Patients were grouped by CTCAE grade ≥ 3 and < 3 complications. RESULTS: Among 83 eligible patients, 33 (40%) had grade ≥ 3 complications and 50 (60%) had grade < 3 complications; anemia and abdominal infections were the most common. There were no perioperative mortalities. Time to initiation of postoperative chemotherapy for patients with grade ≥ 3 and grade < 3 events was 34 days (range, 18-60) and 31 days (range, 21-43), respectively (P = .017). Median progression-free survival (PFS) did not significantly differ between patients with grade ≥ 3 and grade < 3 complications (11.2 months [95% CI: 9.3-14.4] vs 14.9 months [95% CI: 11.3-16.5], respectively; P = .186), nor did median overall survival (OS) (46.9 months [95% CI: 34-NE] vs 68.2 months [95% CI: 52.1-NE], respectively; P = .053). CONCLUSION: Postoperative complications following SCS with or without HIPEC were associated with slight delays in chemotherapy initiation but did not significantly impact oncologic outcomes.
引用
- Praiss AM, Zhou Q, Iasonos A, et al. Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial. Gynecol Oncol. 2023. PMID: 36804618. doi:10.1016/j.ygyno.2023.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。